 Full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with pre-treated non-small cell lung cancer NSCLC harboring a KRASG12C mutation Late-breaking data on adagrasib in patients with KRASG12C-mutated NSCLC with active and untreated central nervous system CNS metastases Company to host Virtual Investor Event on Monday, June 6, 2022 at 8 PM ET7 PM CT to discuss highlights from ASCO 2022 SAN DIEGO , April 27, 2022 PRNewswire -- Mirati Therapeutics, Inc. Nasdaq: MRTX, a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer NSCLC at the 2022 American Society of Clinical Oncology ASCO Annual Meeting taking place June 3 to 7, 2022 in Chicago, IL. Mirati continues to develop adagrasib with the goal of having a meaningful impact on patients with lung cancer, said Charles Baum, M.D. 